Salisbury Foundation Trust

FOI_6540

Internal Reference Number: FOI_6540

Date Request Received: 01/04/2022 00:00:00

Date Request Replied To: 27/04/2022 00:00:00

This response was sent via: By Email

Request Summary: Breast Cancer Treatment

Request Category: Private Individuals

 
Question Number 1:
In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:



• Abemaciclib (Verzenios) + aromatase inhibitor *

• Abemaciclib (Verzenios) + Fulvestrant (Faslodex)

• Alpelisib (Piqray) + Fulvestrant (Faslodex)

• Atezolizumab (Tecentriq)**

• Bevacizumab (Avastin)

• Eribulin (Halaven)

• Everolimus (Afinitor) + Exemestane

• Fulvestrant (Faslodex) as a single agent

• Gemcitabine + paclitaxel

• Herceptin (Trastuzumab) + paclitaxel

• Herceptin (Trastuzumab) as a single agent

• Lapatinib (Tyverb)

• Neratinib (Nerlynx)

• Olaparib (Lynparza)

• Palbociclib (Ibrance) + aromatase inhibitor*

• Palbociclib (Ibrance) + Fulvestrant (Faslodex)

• Pertuzumab (Perjeta) + trastuzumab + docetaxel

• Ribociclib (Kisqali) + aromatase inhibitor*

• Ribociclib (Kisqali) + Fulvestrant (Faslodex)

• Talazoparib (Talzenna)

• Trastuzumab emtansine (Kadcyla)

• Other active systemic anti-cancer therapy **

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

**eg. docetaxel, vinorelbine or capecitabine as a single agent
 
Answer To Question 1:
abemaciclib + aromatase inhibitor <5
Abemaciclib +fulvestrant <5
Alpelisib + fulvestrant; atezolizumab; bevacizumab 0
Eribulin <5
Everolimus + exemestane <5
Fulvestrant single agent 0
Gemcitabine +paclitaxel 0
Trastzumab +paclitaxel 5 – unable to count individuals on brands such as Herceptin
Trastuzumab single agent 8
Lapatinib 0
Neratinib <5
Olaparib <5
Palbociclib + aromatase inhibitor 33
Palbocicilb + fulvestrant <5
Pertuzumab + treastuzumab + docetaxel 8
Ribociclic (both responses); talazoparib 0
Trastuzumab emtansine 7
Unable to answer about other SACT
 
Question Number 2:
For the above patients, how many of these received their first ever dose for each product line?
 
Answer To Question 2:
13
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

Salisbury NHS Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 Salisbury NHS Foundation Trust
Trust Values